Merus (NASDAQ:MRUS) Price Target Raised to $91.00 at BMO Capital Markets

Merus (NASDAQ:MRUSFree Report) had its price target raised by BMO Capital Markets from $84.00 to $91.00 in a report published on Tuesday, Benzinga reports. BMO Capital Markets currently has an outperform rating on the biotechnology company’s stock.

Several other research analysts have also commented on MRUS. StockNews.com lowered shares of Merus from a hold rating to a sell rating in a report on Wednesday, May 22nd. Bank of America boosted their price target on shares of Merus from $52.00 to $61.00 and gave the stock a buy rating in a research report on Friday, May 24th. HC Wainwright reiterated a buy rating and issued a $65.00 target price on shares of Merus in a report on Friday, May 24th. Truist Financial boosted their price target on shares of Merus from $69.00 to $88.00 and gave the company a buy rating in a report on Tuesday. Finally, Guggenheim boosted their price objective on shares of Merus from $57.00 to $93.00 and gave the company a buy rating in a research report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, Merus currently has an average rating of Moderate Buy and a consensus target price of $71.20.

Read Our Latest Analysis on MRUS

Merus Trading Down 4.9 %

Shares of MRUS stock opened at $50.36 on Tuesday. The company’s fifty day simple moving average is $45.93 and its 200-day simple moving average is $39.02. Merus has a 52 week low of $19.81 and a 52 week high of $61.61. The company has a market cap of $2.96 billion, a PE ratio of -18.18 and a beta of 1.10.

Merus (NASDAQ:MRUSGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.24. The firm had revenue of $7.89 million for the quarter, compared to the consensus estimate of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. Equities research analysts expect that Merus will post -3.15 EPS for the current fiscal year.

Institutional Trading of Merus

Several large investors have recently modified their holdings of MRUS. Quadrant Capital Group LLC raised its stake in Merus by 37.7% during the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 343 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Merus in the 1st quarter worth about $72,000. Tower Research Capital LLC TRC grew its holdings in shares of Merus by 64.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 828 shares during the last quarter. SG Americas Securities LLC bought a new stake in Merus during the 1st quarter worth about $108,000. Finally, Exchange Traded Concepts LLC grew its holdings in Merus by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 1,459 shares during the last quarter. 96.14% of the stock is owned by institutional investors.

About Merus

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Featured Articles

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.